Overview

Safety and Efficacy of Brilaroxazine (RP5063) in Patients With an Acute Exacerbation of Schizophrenia, Then 52-Week Open-label Extension

Status:
Not yet recruiting

Trial end date:
2022-12-20

Target enrollment:

Participant gender:

Summary

This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily. The aim of this study is to also assess the long-term tolerability of these tablets over a period of 52 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Reviva Pharmaceuticals

Treatments:

RP5063